There may be a dual role of ?-secretase in AD. The cleavage of APP by ?-secretase is key in the pathogenesis of AD and amyloid accumulation in the brain. As such, ?-secretase has been targeted for years for development of AD therapies and ?-secretase inhibitors (GSIs). Most recently it was shown that a mutation in presenilin affecting ?-secretase activity may impair microglial phagocytosis of A? and promote amyloid accumulation. Because GSIs may impair salutary microglia activity via inhibition of Notch signaling pathway, we seek to develop a new class of flavonoids GSIs that can reduce ?-APP cleavage yet minimize their potential negative effect on microglia phagocytosis activity. Optimally we would seek to do the former while promoting the latter. Turning to diosmin's efficacy as promoting both anti-amyloidogenic APP processing and microglial phagcytosis of A?? we have recently shown that the treatment of Tg2576 mice with diosmin markedly reduces cerebral A?40,42 species and consequently lowers A? deposits. Based on this finding, its diosmetin metabolite becomes our focus on preliminary studies. These results indicate that diosmin/diosmetin not only reduces A? by inhibiting ?-APP cleavage but also decreases hyperphosphorylated tau by modulating GSK-3? activation and enhances microglial anti-inflammatory and phagocytotic phenotype switching. These new results fully support our present hypothesis that diosmin could have a therapeutic effect in AD by reducing cognitive impairment while also reducing cerebral ?-amyloid levels, tau pathology and microglial/neuroinflammation. In this application, the flavonoid-diosmin will be orally administered to 3XTg-AD mice before (prophylactic treatment group) or after (therapeutic treatment group) development of AD-like pathology. Groups of untreated non-transgenic littermates will be compared to the transgenic treatment groups. Oral administration of diosmin to these mice will begin at 4 and 6 months of age and continued for 6 months.
For Aim 1, cognitive testing will be done at several ages following the administration.
For Aim 2, we will sacrifice these mice at several ages to examine histological and biochemical endpoints related to amyloid deposition and tau hyperphosphorylation and correlate pathological changes with cognitive performance.
For Aim 3, we will test the hypothesis that diosmin treatment preserves the anti-inflammatory and phagocytic phenotype in primary microglia from young and aged 3XTg-AD mice. These studies could lay the foundation for AD clinical trials with diosmin diet supplementation in the near future.
|Sawmiller, Darrell; Habib, Ahsan; Li, Song et al. (2016) Diosmin reduces cerebral AÎ² levels, tau hyperphosphorylation, neuroinflammation, and cognitive impairment in the 3xTg-AD mice. J Neuroimmunol 299:98-106|
|Li, Song; Hou, Huayan; Mori, Takashi et al. (2015) Swedish mutant APP-based BACE1 binding site peptide reduces APP Î²-cleavage and cerebral AÎ² levels in Alzheimer's mice. Sci Rep 5:11322|
|Deng, Juan; Habib, Ahsan; Obregon, Demian F et al. (2015) Soluble amyloid precursor protein alpha inhibits tau phosphorylation through modulation of GSK3Î² signaling pathway. J Neurochem 135:630-7|